Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,503.20
(
0.00%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
108.52
(
0.24%
)
Bitcoin
67,360.66
(
2.13%
)
News Focus
News Focus
Post# of 257302
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Rocky3 post# 217148

Sunday, 03/04/2018 7:21:24 PM

Sunday, March 04, 2018 7:21:24 PM

Post# of 257302

ABBV taking significant NRx market share, but duration will limit TRx market share.

I think you overestimated the duration advantage of GILD's HCV regimens compared to Mavyret in your outlook for TRx market share: #msg-138970464.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today